Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial Data during the Annual Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

SAN DIEGO, Feb. 13, 2023 /PRNewswire/ — Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that it has been selected by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant…

Click here to view original post